In the KATHERINE clinical trial, the invasive DFS at 3 years of HER2-positive breast cancer patients with residual invasive disease who received T-DM1 was 88.3%, higher than patients receiving trastuzumab (HR = 0.5, p < 0.001) (9). The gene discussed is ERBB2; the disease is breast carcinoma.